Table 3.
Studies of pathways hindering cGAS–STING activation of interferon signaling after ionizing radiation.
| Ref | Radiation Dose | Cells/Model | Cell Type | Responses |
|---|---|---|---|---|
| [101] | 20 Gy b 8 Gy b |
TSA in vivo (s.c.) a TSA in vitro |
mouse mammary carcinoma | ↑ e efficacy with cellular CASP3-deficiency ↑ type I IFN a with cellular CASP3-deficiency |
| [22] | 40 Gy 15 Gy |
MC38 in vitro MC38 in vivo (s.c.) |
mouse colon adenocarcinoma | ↑ type I IFN with CASP9-deficiency ↑ efficacy with CASP9-deficiency |
| [102] | 20 Gy | MC38 in vivo (s.c) | mouse colon adenocarcinoma | ↑ efficacy, ↑ type I IFN, and ↑ DC priming capacity with host non-canonical NF-κB-deficiency |
| [25] | 8 Gy b × 3 a + αCTLA4 8 Gy b × 3 |
TSA in vivo (s.c.) TSA in vitro |
mouse mammary carcinoma | ↓ d systemic (abscopal) efficacy with induction of cellular Trex1 ↓ type I IFN with induction of cellular Trex1 |
| [27] | 8 Gy b × 3 | TSA in vitro | mouse mammary carcinoma | ↓ dsDNA a cargo in exosomes with induction of cellular Trex1 |
a Abbreviations: double-stranded DNA (dsDNA); interferon (IFN); subcutaneous (s.c.); 3 doses (× 3). b External beam X-ray irradiator. d Decreased. e Increased.